Comparison of Tenofovir and Entecavir in the Prevention of Hepatocellular Carcinoma Occurrence in Patients with Chronic Hepatitis B.

Liver Cancer

Department of Medical Sciences, Gastroenterology Unit, Ospedali Riuniti di Foggia, Foggia, Italy.

Published: June 2021

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237790PMC
http://dx.doi.org/10.1159/000512780DOI Listing

Publication Analysis

Top Keywords

comparison tenofovir
4
tenofovir entecavir
4
entecavir prevention
4
prevention hepatocellular
4
hepatocellular carcinoma
4
carcinoma occurrence
4
occurrence patients
4
patients chronic
4
chronic hepatitis
4
comparison
1

Similar Publications

Background: There is increasing recognition that the interpretation of active-controlled HIV prevention trials should consider the counterfactual placebo HIV incidence rate, that is, the rate that would have been observed if the trial had included a placebo control arm. The PrEPVacc HIV vaccine and pre-exposure prophylaxis trial (NCT04066881) incorporated a pre-trial registration cohort partly for this purpose. In this article, we describe our attempts to model the counterfactual placebo HIV incidence rate from the registration cohort.

View Article and Find Full Text PDF

Rationale & Objective: Longitudinal research on chronic kidney disease (CKD) in sub-Saharan Africa is sparse, especially among people living with HIV (PLWH). We evaluated the incidence of CKD among PLWH compared with HIV-uninfected controls in Tanzania.

Study Design: Prospective cohort study.

View Article and Find Full Text PDF

[Comparison of the effects of tenofovir amibufenamide and tenofovir alafenamide on lipid metabolism in the body].

Zhonghua Gan Zang Bing Za Zhi

December 2024

Department of Infectious Diseases and Hepatology, Yichun People's Hospital, Yichun336000, China.

To compare the effectiveness and safety profile of tenofovir amibufenamide (TMF) and tenofovir alafenamide (TAF), especially the effects on lipid metabolism in the treatment of chronic hepatitis B. A retrospective study was conducted on the virological response rate, biochemical response rate, renal function indicators, and lipid metabolism status of 159 cases with chronic hepatitis B (72 cases with TMF and 87 cases with TAF) after 48 weeks of antiviral treatment. The effects of the two drugs on lipid metabolism were further explored through cell and animal experiments.

View Article and Find Full Text PDF

Introduction: The BIC-T&T study aimed to determine the efficacy of bictegraviremtricitabine/tenofovir alafenamide (BIC/F/TAF) and darunavir/cobicistat/emtricitabinetenofovir alafenamide (DRV/c/F/TAF) at suppressing viral load in a two-arm, open-label, multi-centre, randomised trial under a UK test-and-treat setting. This sub-study aimed to evaluate potential off-target cardiovascular impact by examining platelet function.

Methods: Platelets were isolated by centrifugation of citrated blood from participants attending Chelsea and Westminster Hospital or St Mary's Hospital at Week 48 following enrolment.

View Article and Find Full Text PDF

Real-world data on treatment outcomes or the quality of large-scale chronic hepatitis B (CHB) treatment programs in sub-Saharan Africa (SSA) is extremely difficult to obtain. In this study, we aimed to provide data on the prevalence and incidence of mortality, loss to follow-up (LFTU), and their associated factors in patients with CHB in three treatment centres in Eritrea. Additional information includes baseline clinical profiles of CHB patients initiated on nucleos(t)ide analogue (NUCs) along with a comparison of treatment with Tenofovir disoproxil fumarate (TDF) vs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!